Catalyst
Slingshot members are tracking this event:
Lilly's (LLY) Olaratumab + Doxorubicin in Soft Tissue Sarcoma Recommended for Approval by European Ad Comm
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| LLY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 16, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
European Medicines Agency, Chmp, Olaratumab, Doxorubicin, Recommendation For Approval
